

*B
Contd'*

52. A composition in dosage unit form useful for inducing regression and/or palliation of cancer diseases in mammals comprising from about one mg. to about 200 mg. per kilogram of body weight per daily dosage unit of a compound selected from the group consisting of 1,4-bis[(2-aminoethyl)-amino]-5,8-dihydroxyanthraquinone, 1,4-bis[2-(methylamino)-ethylamino]-5,8-dihydroxyanthraquinone, 1,4-bis[2-(1,3-oxazolidin-1-yl)ethylamino]-5,8-dihydroxyanthraquinone, 1,4-bis[2-(tetrahydro-1,3-oxazin-1-yl)ethylamino]-5,8-dihydroxyanthraquinone, 1,4-bis[2-(1,3-oxazolidin-2-one-1-yl)ethylamino]-5,8-dihydroxyanthraquinone, 1,4-bis[2-(tetrahydro-1,3-oxazin-2-one-1-yl)ethylamino]-5,8-dihydroxyanthraquinone, the leuco bases thereof, the tautomers thereof and the pharmacologically acceptable acid-addition salts thereof; in association with a pharmaceutical carrier.

REMARKS

The preceding amendments are proper at this time in order to present the claims in a more consistent form for examination.

The Examiner's attention is hereby drawn to the fact of the issuance of the parent application, Serial No. 923,602 as U.S. Patent No. 4,197,249

Respectfully submitted,

Edward A. Conroy, Jr.
Edward A. Conroy, Jr.
Attorney for Applicants
Registration No. 19,087

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner of Patents and Trademarks, Washington, D. C. 20231, on April 11, 1980
(Date of Deposit)

EDWARD A. CONROY, JR.
Name of Applicant, Assignee, or
Registered Representative

Edward A. Conroy, Jr.
Signature
11-IV-80
Date of Signature